MARCO and lymphoma: Importantly, GVT activity was preserved, as evidenced by improved survival in mice with A20 lymphoma treated with IMPs.<h4>Conclusions</h4>Systemic IMPs reduce clinical GVHD signs and improve survival, likely by decreasing inflammatory monocytes via MARCO and expanded regulatory T-cells numbers, while maintaining GVT activity.